TWI911130B - 艾維頓尼(ivosidenib)之型式及藥學組成物 - Google Patents

艾維頓尼(ivosidenib)之型式及藥學組成物

Info

Publication number
TWI911130B
TWI911130B TW114126745A TW114126745A TWI911130B TW I911130 B TWI911130 B TW I911130B TW 114126745 A TW114126745 A TW 114126745A TW 114126745 A TW114126745 A TW 114126745A TW I911130 B TWI911130 B TW I911130B
Authority
TW
Taiwan
Prior art keywords
type
ivosidenib
pharmaceutical composition
solid
amino
Prior art date
Application number
TW114126745A
Other languages
English (en)
Chinese (zh)
Other versions
TW202543623A (zh
Inventor
重輝 顧
雅各 Ｐ 塞斯摩爾
仕傑 張
Original Assignee
法商施維雅藥廠
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 法商施維雅藥廠 filed Critical 法商施維雅藥廠
Publication of TW202543623A publication Critical patent/TW202543623A/zh
Application granted granted Critical
Publication of TWI911130B publication Critical patent/TWI911130B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
TW114126745A 2018-07-06 2019-07-05 艾維頓尼(ivosidenib)之型式及藥學組成物 TWI911130B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862694596P 2018-07-06 2018-07-06
US62/694,596 2018-07-06

Publications (2)

Publication Number Publication Date
TW202543623A TW202543623A (zh) 2025-11-16
TWI911130B true TWI911130B (zh) 2026-01-01

Family

ID=69059942

Family Applications (2)

Application Number Title Priority Date Filing Date
TW114126745A TWI911130B (zh) 2018-07-06 2019-07-05 艾維頓尼(ivosidenib)之型式及藥學組成物
TW108123796A TWI902665B (zh) 2018-07-06 2019-07-05 艾維頓尼(ivosidenib)之型式及藥學組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
TW108123796A TWI902665B (zh) 2018-07-06 2019-07-05 艾維頓尼(ivosidenib)之型式及藥學組成物

Country Status (18)

Country Link
US (1) US12264148B2 (https=)
EP (2) EP3817744A4 (https=)
JP (2) JP7621242B2 (https=)
KR (2) KR102919157B1 (https=)
CN (1) CN112367995A (https=)
AU (2) AU2019299352B2 (https=)
BR (1) BR112021000156A2 (https=)
CA (1) CA3103498A1 (https=)
EA (1) EA202190217A1 (https=)
IL (2) IL315423B1 (https=)
MA (1) MA53099A (https=)
MX (2) MX2021000068A (https=)
PH (1) PH12021550017A1 (https=)
SG (1) SG11202012763TA (https=)
TW (2) TWI911130B (https=)
UA (1) UA129800C2 (https=)
WO (1) WO2020010058A1 (https=)
ZA (1) ZA202008034B (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020327013B2 (en) 2019-08-08 2026-03-26 Les Laboratoires Servier A method for preparing Ivosidenib and an intermediate thereof
GB201912411D0 (en) * 2019-08-29 2019-10-16 Johnson Matthey Plc Crystalline forms of ivosidenib
AR133410A1 (es) 2023-08-01 2025-09-24 Servier Lab Cocristal de un inhibidor de idh1, proceso de preparación del mismo, composiciones farmacéuticas del mismo, y métodos de tratamiento que implican el mismo

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015138839A1 (en) * 2014-03-14 2015-09-17 Agios Pharmaceuticals, Inc. Pharmaceutical compositions of therapeutically active compounds

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120121515A1 (en) 2009-03-13 2012-05-17 Lenny Dang Methods and compositions for cell-proliferation-related disorders
WO2011050210A1 (en) 2009-10-21 2011-04-28 Agios Pharmaceuticals, Inc. Methods and compositions for cell-proliferation-related disorders
RU2013144975A (ru) * 2011-04-08 2015-05-20 Пфайзер Инк. Кристаллические и некристаллические формы тофацитиниба и фармацевтическая композиция, содержащая тофацитиниб, и усилитель проникновения
US9474779B2 (en) 2012-01-19 2016-10-25 Agios Pharmaceuticals, Inc. Therapeutically active compositions and their methods of use
AR092439A1 (es) * 2012-09-06 2015-04-22 Bayer Healthcare Llc Composicion farmaceutica recubierta que contiene regorafenib
MA39725B1 (fr) * 2014-03-14 2021-09-30 Les Laboratoires Servier Sas Compositions pharmaceutiques de composés thérapeutiquement actifs
KR102699521B1 (ko) * 2015-10-15 2024-08-26 르 라보레또레 쎄르비에르 악성 종양의 치료를 위한 조합물 요법
MA43640A (fr) * 2016-02-26 2018-11-28 Agios Pharmaceuticals Inc Inhibiteurs de idh1 pour le traitement de cancers hématologiques et de tumeurs solides
US11066390B2 (en) 2017-11-27 2021-07-20 Assia Chemical Industries Ltd. Solid state forms of Ivosidenib

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015138839A1 (en) * 2014-03-14 2015-09-17 Agios Pharmaceuticals, Inc. Pharmaceutical compositions of therapeutically active compounds

Also Published As

Publication number Publication date
UA129800C2 (uk) 2025-08-06
EP3817744A1 (en) 2021-05-12
MA53099A (fr) 2021-05-12
CA3103498A1 (en) 2020-01-09
AU2019299352A1 (en) 2021-01-07
ZA202008034B (en) 2021-10-27
KR102919157B1 (ko) 2026-01-27
US20210323944A1 (en) 2021-10-21
TW202019419A (zh) 2020-06-01
IL315423B1 (en) 2026-04-01
TWI902665B (zh) 2025-11-01
TW202543623A (zh) 2025-11-16
AU2019299352B2 (en) 2025-02-27
KR20210029775A (ko) 2021-03-16
PH12021550017A1 (en) 2021-09-13
EP3817744A4 (en) 2022-07-13
JP2024150784A (ja) 2024-10-23
MX2023011687A (es) 2023-10-19
EP4603147A3 (en) 2025-10-01
IL279877A (en) 2021-03-01
AU2025203835A1 (en) 2025-06-12
JP2021529805A (ja) 2021-11-04
CN112367995A (zh) 2021-02-12
SG11202012763TA (en) 2021-02-25
JP7621242B2 (ja) 2025-01-24
BR112021000156A2 (pt) 2021-04-06
MX2021000068A (es) 2021-03-25
WO2020010058A1 (en) 2020-01-09
US12264148B2 (en) 2025-04-01
EA202190217A1 (ru) 2021-04-16
IL315423A (en) 2024-11-01
EP4603147A2 (en) 2025-08-20
KR20250164882A (ko) 2025-11-25

Similar Documents

Publication Publication Date Title
AU2019232825B2 (en) Pharmaceutical compositions of therapeutically active compounds
CA2942072C (en) Pharmaceutical compositions and use of (s)-1-(2-chlorophenyl)-2-((3,3-difluorocyclobutyl)amino)-2-oxoethyl)-1-( 4-cyanopyridin-2-yl)-n-( 5-fluoropyridin-3-yl)-5-oxopyrrolidine-2-carboxamide
JP2024150784A (ja) イボシデニブ形態および医薬組成物
HK40129554A (en) Ivosidenib forms and pharmaceutical compositions
EA048347B1 (ru) Формы ивосидениба и фармацевтические композиции
EA053032B1 (ru) Формы ивосидениба и фармацевтические композиции
BR122023021440B1 (pt) Composições farmacêuticas para tratar câncer
EA051161B1 (ru) Фармацевтические композиции терапевтически активных соединений
HK1233185B (en) Pharmaceutical compositions of therapeutically active compounds